Benzinga
Benzinga
Benzinga
sabato, settembre 19

VivoPower PLC

VIVONASDAQ
Trade with Public
Trade with Public
$3.86
0.133.49%
In chiusura: Sep 18, 5:00 PM EST
$3.89
0.030.78%
Post-mercato: 7:10 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

VivoPower Analyst Price Targets

Wall Street analyst price targets and consensus rating for VivoPower (VIVO).

Price Target Range — 1 Quarters

Analyst Consensus — 1 Analysts

1Buy
Consensus RatingOutperform# Analysts1Avg. Consensus PT$10Upside to Avg. PT+157.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Jul 13, 2026Noble Capital MarketsMichael KupinskiInitiateOutperform$10

Analyst Ratings News

PRO
Noble Capital Markets Initiates Coverage On VivoPower with Outperform Rating, Announces Price Target of $10

Noble Capital Markets analyst Michael Kupinski initiates coverage on VivoPower (NASDAQ:VIVO) with a Outperform rating and announces Price Target of $10.
Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022

 
Benzinga Insights

PRO
HC Wainwright & Co. Downgrades Meridian Bioscience to Neutral, Raises Price Target to $34

HC Wainwright & Co. analyst Yi Chen downgrades Meridian Bioscience (NASDAQ:VIVO) from Buy to Neutral and raises the price target from $30 to $34.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $30

HC Wainwright & Co. analyst Yi Chen maintains Meridian Bioscience (NASDAQ:VIVO) with a Buy and raises the price target from $28 to $30.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $28

HC Wainwright & Co. analyst Yi Chen maintains Meridian Bioscience (NASDAQ:VIVO) with a Buy and raises the price target from $27 to $28.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Lowers Price Target to $27

HC Wainwright & Co. analyst Yi Chen maintains Meridian Bioscience (NASDAQ:VIVO) with a Buy and lowers the price target from $30 to $27.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved